NCT01608516

Brief Summary

The present study aims at assessing the ability of 68Ga-NODAGA-RGD PET/CT for the detection of inflammatory atheromatous plaques in the carotid arteries, compared to 18F-FDG PET/CT, MRI and US and to determine the contribution of each imaging technique. Current gold standard for inflammation is histopathology. Hypothesis : 68Ga-NODAGA-RGD might give a better initial evaluation of patients with atheromatous plaques in the carotid artery eligible for endarterectomy.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
20

participants targeted

Target at P25-P50 for phase_1

Timeline
Completed

Started Apr 2012

Longer than P75 for phase_1

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2012

Completed
15 days until next milestone

First Submitted

Initial submission to the registry

April 16, 2012

Completed
2 months until next milestone

First Posted

Study publicly available on registry

May 31, 2012

Completed
12.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2024

Completed
Last Updated

June 20, 2024

Status Verified

June 1, 2024

Enrollment Period

12.7 years

First QC Date

April 16, 2012

Last Update Submit

June 17, 2024

Conditions

Keywords

PET/CT68Ga-NODAGA-RGD18F-FDGMRIUS ultrasoundinflammatory atheromatous plaqueendarterectomy

Outcome Measures

Primary Outcomes (1)

  • Comparison of each method of imaging for the detection of inflammatory atheromatous plaques

    The potential of each of the methods of imaging for the detection of inflammatory atheromatous plaques will be compared. For that purpose, the capacity of every criterion of primary assessment to determine the presence of an unstable plaque will be studied compared with the histopathological sample.

    Within1 month of endarterectomy

Secondary Outcomes (2)

  • Comparison of AUC of the imaging methods

    Within1 month of endarterectomy

  • Analysis of histopathological sample of endarterectomy

    Within1 month of endarterectomy

Study Arms (1)

68Ga-NODAGA-RGD radiotracer

EXPERIMENTAL

All patients will undergo a 68Ga-NODAGA-RGD PET/CT, a 18F-FDG PET/CT, a MRI and a US.

Drug: 68Ga-NODAGA-RGD PET/CT

Interventions

200 MBq 68 Ga-NODAGA-RGD will be administered i.v. and images centred on the carotid area acquired

68Ga-NODAGA-RGD radiotracer

Eligibility Criteria

Age18 Years - 85 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • age \<= 85 years
  • Karnofsky \>= 80%
  • patient with indication ofr carotid endarterectomy
  • signed consent form

You may not qualify if:

  • indication for surgery other than endarterectomy \<14 days
  • contraindication to surgery
  • contraindication to MRI
  • contraindication to gadolinium injection (stage 4/5 kidney insufficiency, GFR\<30ml/min/1.73m2)
  • pregnancy, breastfeeding
  • lack of discernment

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Centre Hospitalier Universitaire Vaudois

Lausanne, Canton of Vaud, 1011, Switzerland

RECRUITING

Related Publications (1)

  • Gnesin S, Mitsakis P, Cicone F, Deshayes E, Dunet V, Gallino AF, Kosinski M, Baechler S, Buchegger F, Viertl D, Prior JO. First in-human radiation dosimetry of 68Ga-NODAGA-RGDyK. EJNMMI Res. 2017 Dec;7(1):43. doi: 10.1186/s13550-017-0288-x. Epub 2017 May 18.

MeSH Terms

Conditions

InflammationPlaque, AtheroscleroticCarotid Artery Diseases

Condition Hierarchy (Ancestors)

Pathologic ProcessesPathological Conditions, Signs and SymptomsPathological Conditions, AnatomicalCerebrovascular DisordersBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesVascular DiseasesCardiovascular Diseases

Study Officials

  • John O. Prior, PhD, MD

    Lausanne University Hospitals

    PRINCIPAL INVESTIGATOR

Central Study Contacts

John O. Prior, PhD, MD

CONTACT

Emmanuel Deshayes, MD

CONTACT

Study Design

Study Type
interventional
Phase
phase 1
Allocation
NA
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Chief of Department of Nuclear Medicine

Study Record Dates

First Submitted

April 16, 2012

First Posted

May 31, 2012

Study Start

April 1, 2012

Primary Completion

December 1, 2024

Study Completion

December 1, 2024

Last Updated

June 20, 2024

Record last verified: 2024-06

Data Sharing

IPD Sharing
Will not share

Locations